NetworkNewsBreaks – Q Biomed Inc. (QBIO) Closes $5.48M Public Offering
Q BioMed (OTCQB: QBIO) recently announced the closing of its public offering of 1,711,875 units at a public offering price of $3.20 per unit for gross proceeds of $5.48 million. Each unit consists of one common share and one warrant. Roth Capital Partners acted as lead placement agent and CIM Securities acted as co-lead placement agent for the offering. The company intends to use the proceeds from the offering toward the launch of its non-opioid FDA approved Strontium Chloride 89 USP Injection (SR89) as well as toward the initiation of various pivotal clinical programs in 2018. "This capital sets up…







